On Sunday, the Food and Drug Administration authorized a third coronavirus vaccine, produced by Johnson & Johnson, for emergency use. This one’s a little different: It’s more shelf-stable than the mRNA vaccines already in distribution, and requires just one dose. Sounds great, right? Yet questions abound about the new vaccine—and the old ones, too.